Navigation Links
MAP Pharmaceuticals Announces Resignation of Chief Medical Officer
Date:2/5/2008

MOUNTAIN VIEW, Calif., Feb. 5 /PRNewswire-FirstCall/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP), an emerging pharmaceutical company, announced today that Stephen B. Shrewsbury, M.B., Ch.B., Chief Medical Officer, will be leaving the company for personal reasons in early March 2008. Dr. Shrewsbury plans to provide consulting services to the company for a period of time after his departure.

"We want to thank Steve for his many contributions and wish him the best in his future endeavors," said Timothy S. Nelson, President and Chief Executive Officer. "Steve has put into place a strong leadership team in the clinical organization to advance our two lead programs for pediatric asthma and migraine through late-stage development."

"I am happy to have played a role in the development of our two lead product candidates, Unit Dose Budesonide (UDB) and MAP0004," stated Stephen B. Shrewsbury, M.B., Ch.B., Chief Medical Officer. "I made the difficult decision to leave MAP Pharmaceuticals for personal reasons and believe that the company is well positioned to move forward with these very promising programs."

About MAP Pharmaceuticals

MAP Pharmaceuticals develops and plans to commercialize new therapies for children and adults who suffer from diseases that the company believes are not treated adequately by currently available medicines. The company uses proprietary inhalation technologies to enhance the therapeutic benefits and commercial attractiveness of proven drugs, while minimizing risk by capitalizing on their known safety, efficacy and commercialization history. The company has several product candidates in clinical development that address large market opportunities, including its two most advanced product candidates: UDB, a proprietary version of nebulized budesonide for the potential treatment of children with asthma; and MAP0004, a proprietary version of orally inhaled dihydroergotamine delivered by MAP Pharmaceuticals' Tempo(TM) inhaler for the potential treatment of migraine. The company is also developing a proprietary combination of an inhaled corticosteroid with a long-acting beta2-agonist for the potential treatment of asthma and chronic obstructive pulmonary disease.


'/>"/>
SOURCE MAP Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
2. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
3. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
4. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
5. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
6. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
7. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
8. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
9. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
10. Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study
11. Class Settlement Could Result in Considerable Savings for Certain Consumers of Prescription Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/18/2017)... ... 2017 , ... A new directory from the Senior Veterans ... connect elderly veterans of America's armed forces to a range of senior care ... on this year's increase in the Veterans Pension with Aid & Attendance for ...
(Date:2/17/2017)... , ... February 17, 2017 , ... ... not kept pace. Enovate Medical has introduced an innovative workstation designed to reduce ... supporting nurses, the Encore Mobile EHR Workstation offers a lightweight, highly mobile, multi-functional ...
(Date:2/17/2017)... ... 2017 , ... Wells Pharmacy Network offers physicians WellsPx3, a ... non-controlled substances plus the ability to manage orders on their desktop or mobile ... electronic prescriptions, according to the Office of the National Coordinator of Health IT, ...
(Date:2/17/2017)... ... February 17, 2017 , ... ... **An FDAnews Webinar**, Feb. 22, 2017 — 1:30 p.m. – 2:30 p.m. ... manufacturers should be asking before selecting an FDA approval pathway? , How ...
(Date:2/17/2017)... Falls Church, VA (PRWEB) , ... February 17, ... ... Devices, Implementing the Steps to Prevent a Warning Letter, **An FDAnews Webinar**, Feb. ... , Do manufacturers distinguish between corrective action (CA) and preventive action ...
Breaking Medicine News(10 mins):
(Date:2/18/2017)... Research and Markets has announced the addition of the "Contraceptives - ... ... the US, Canada , Japan , ... Latin America , and Rest of World. Annual estimates and forecasts ... analysis is provided for these markets. Market data and analytics are derived ...
(Date:2/17/2017)... 2017  Ethicon, Inc. today announced a definitive ... held medical device company that manufactures and markets ... novel minimally invasive device for the surgical treatment ... enable Ethicon to offer patients a safe and ... surgical procedure. 1 This LINX ...
(Date:2/17/2017)... Theravance Biopharma, Inc. (NASDAQ: ... announced the presentation of positive clinical data for ... kinase (JAK) inhibitor designed to be intestinally restricted, ... European Crohn,s and Colitis Organization (ECCO). In a ... its completed Phase 1 study of single-ascending and ...
Breaking Medicine Technology: